In a report released today, Alethia Young from Cantor Fitzgerald reiterated a Buy rating on Alnylam Pharma (NASDAQ: ALNY), with a price target of $135. The company’s shares opened today at $88.18, close to its 52-week low of $84.48.
Young commented:
“We reiterate our Overweight rating and 12-month price target of $135 on shares of ALNY. We hosted Alnylam’s CEO a fireside chat. Key topics discussed were ONPATTRO launch, givosiran recent data, inclisiran, and lumasiran. As it relates to ongoing ONPATTRO launch, we will get an update on early patient adds after 6 weeks at the quarterly update. There are ~3K patients under care who would fit the ONPATTRO label. We also think that there could be a small bolus of patients, but management wouldn’t exactly confirm it, so we are waiting to hear color on the quarterly call. We also note that Akcea’s (AKCA, NC) potential US approval for Inotersen is October 6th (which is a Sat, so expect a decision on Friday).”
According to TipRanks.com, Young is a 4-star analyst with an average return of 8.5% and a 51.6% success rate. Young covers the Healthcare sector, focusing on stocks such as Vertex Pharmaceuticals, Puma Biotechnology, and Intercept Pharma.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Alnylam Pharma with a $146.77 average price target, which is a 66.4% upside from current levels. In a report issued on September 27, Chardan Capital also reiterated a Buy rating on the stock with a $180 price target.
.
See today’s analyst top recommended stocks >>
The company has a one-year high of $153.99 and a one-year low of $84.48. Currently, Alnylam Pharma has an average volume of 894.6K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. It is the translation of RNAi as a new class of innovative medicines with a core focus on RNAi therapeutics for the treatment of genetically defined diseases.
